SRR1375271
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.433
- MYOGENESIS+0.224
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.162
- APICAL_SURFACE+0.155
- SPERMATOGENESIS+0.121
- APICAL_JUNCTION+0.111
- WNT_BETA_CATENIN_SIGNALING+0.090
- TNFA_SIGNALING_VIA_NFKB+0.046
- PANCREAS_BETA_CELLS+0.038
- ESTROGEN_RESPONSE_EARLY+0.034
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.582
- MYC_TARGETS_V1-0.566
- MTORC1_SIGNALING-0.441
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.426
- PROTEIN_SECRETION-0.411
- ADIPOGENESIS-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.379
- FATTY_ACID_METABOLISM-0.353
- MYC_TARGETS_V2-0.350
- DNA_REPAIR-0.337
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1430972 | GTEX | — | 0.933 |
| 2 | SRR1419714 | GTEX | — | 0.917 |
| 3 | C3N-00175 | — | cohortA1 | 0.913 |
| 4 | SRR8613808 | — | D | 0.912 |
| 5 | 82978 | EPN | Supratentorial EPN | 0.910 |
| 6 | BS_J71N7D09 | Med | Medulloblastoma | 0.909 |
| 7 | SRR6013488 | — | cohortA1 | 0.908 |
| 8 | BS_YK6VQ9SJ | DNET | — | 0.908 |
| 9 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.908 |
| 10 | MDT-AP-1190 | Med | Medulloblastoma | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.433 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.224 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.162 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.155 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.121 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.111 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.046 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.038 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.034 | Inavolisib | — uncovered |
| COAGULATION | 0.026 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.011 | Remibrutinib | — uncovered |
| HYPOXIA | 0.006 | Idelalisib | — uncovered |